Effects of MASLD, chronic liver disease and GLP-1RA therapy Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in obese individuals with insulin resistance (119, 120)
Ingredients Purified water, ethylhexyl palmitate, squalane, cetyl alcohol, dimethyl MEA, algae extract, pullulan, stearic acid, glycerol stearate, PEG-100 stearate, Copper Tripeptide-1 (GHK-Cu), phenoxyethanol, PPG 2 myristyl ether propionate, C10-30 cholesterol/lanosterol esters, polysorbate 80, allantoin, aloe barbadensis (aloe vera) gel, glycine, leucine, tocophersolan (Vitamin E), mixed (alpha, beta, gamma, delta) tocotrienols, mixed (alpha, beta, gamma, delta) tocopherols, ubiquinone (CoQ-10), and xanthophyll (lutein)
Two peptides that enhance each other results may deliver more value than higher doses of a single peptide at the same total cost
Known contraindications vary by peptide
Improved Hormonal Signaling Healthy intestinal cells produce hormones that regulate appetite and glucose metabolism
However, it is very possible that ketamine treatments may cause bladder irritation